Reactive dicarbonyl electrophiles (RDS)

Reactive dicarbonyl electrophiles (RDS), such as methylglyoxal, glyoxal, and isolevuglandins, are highly reactive metabolic byproducts generated through pathways such as glycolysis, lipid peroxidation, and polyol metabolism (PMID: 24511154). These molecules are characterized by the presence of two carbonyl groups, which facilitates rapid covalent modification of nucleophilic residues on proteins (primarily lysine and arginine) and DNA, leading to the formation of Advanced Glycation End-products (AGEs) (PMID: 31503876). This process, known as dicarbonyl stress, causes protein cross-linking, enzyme inactivation, and the induction of pro-inflammatory signaling, playing a central role in the progression of diabetic complications, atherosclerosis, and neurodegenerative diseases like Alzheimer's (PMID: 21993154). Therapeutic intervention involves the use of dicarbonyl scavengers—small molecules that contain nucleophilic groups designed to react with and neutralize these electrophiles before they can damage endogenous targets (PMID: 30654071). Examples of such agents include 2-hydroxybenzylamine (2-HOBA) and pyridoxamine, which have shown potential in reducing oxidative damage and improving vascular function in clinical and preclinical models (PMID: 31138538). These drugs act as molecular traps, effectively reducing the burden of dicarbonyl-mediated damage and mitigating chronic inflammation and oxidative stress.

Other names

Reactive dicarbonyl species1,2-dicarbonylsDicarbonyl stress mediatorsReactive aldehydesDicarbonyls

Small molecule scavenging and covalent sequestration of reactive carbonyl groups to prevent the modification of endogenous proteins and DNA (PMID: 30654071).